Table 1.
Sample characteristics by adherence and viral load status
| Total (N=750) | Adherencea
|
pb | Viral load
|
pc | |||
|---|---|---|---|---|---|---|---|
| <85% (n=226) | ≥85% (n=518) | Undetectable (n=549) | Detectable(n=163) | ||||
| Regimen type (n,%) | 0.043 | <0.001 | |||||
| Single Tablet Regimen | 166(22.13) | 39(23.49) | 127(76.51) | 143(91.08) | 14(8.92) | ||
| Single-dose Multi-Tablet Regimen | 300(40.00) | 92(31.08) | 204(68.92) | 200(70.67) | 83(29.33) | ||
| Multi-dose Multi-Tablet Regimen | 284(37.87) | 95(33.69) | 187(66.31) | 206(75.74) | 66(24.26) | ||
| Other characteristics (n,%) | |||||||
| Age [21–72 yrs] | 0.011 | <0.001 | |||||
| 21–30 yrs | 51(6.81) | 23(46.94) | 26(53.06) | 25(56.82) | 19(43.18) | ||
| 31–40 yrs | 95(12.68) | 35(36.84) | 60(63.16) | 66(72.53) | 25(27.47) | ||
| 41–50 yrs | 328(43.79) | 89927.38) | 236(72.62) | 235(75.56) | 76(24.44) | ||
| 51–72 yrs | 275(36.72) | 78(28.47) | 196(71.53) | 223(84.15) | 42(15.85) | ||
| Gender (female) | 0.560 | 0.033 | |||||
| Male | 531(70.99) | 161(30.61) | 365(69.39) | 379(74.90) | 127(25.10) | ||
| Female | 217(29.01) | 65(30.09) | 151(69.91) | 168(82.35) | 36(17.65) | ||
| Ethnicity | 0.219 | 0.334 | |||||
| African American | 679(90.53) | 207(30.76) | 466(69.24) | 499(77.60) | 144(22.40) | ||
| Other | 71(9.47) | 19(26.76) | 52(73.24) | 50(72.46) | 19(27.54) | ||
| Years since infection | 0.963 | 0.162 | |||||
| ≤10 years | 228(30.60) | 68(30.09) | 158(69.91) | 156(72.56) | 59(27.44) | ||
| 10–20 years | 300(40.27) | 95(31.77) | 204(68.23) | 226(79.02) | 60(20.98) | ||
| ≥20 years | 217(29.13) | 63(29.30) | 152(70.70) | 164(79.23) | 43(20.77) | ||
| HIV symptoms | 0.002 | 0.014 | |||||
| 0–3 symptoms | 403(53.73) | 104(26.00) | 300(74.00) | 303(79.74) | 77(20.26) | ||
| 4–6 symptoms | 183(24.40) | 62(33.88) | 123(66.12) | 137(79.19) | 36(20.81) | ||
| 7–14 symptoms | 164(21.87) | 60(37.27) | 100(62.73) | 109(68.55) | 50(31.45) | ||
| Depressive symptoms | 0.002 | 0.111 | |||||
| CESD(≤16) | 406(54.13) | 103(25.50) | 301(74.50) | 305(79.43) | 79(20.57) | ||
| CESD(>16) | 344(45.87) | 123(36.18) | 217(63.82) | 244(74.39) | 84(25.61) | ||
| Self-efficacy [0–10] | 0.086 | 0.355 | |||||
| Low (<6) | 161(21.50) | 59(37.34) | 99(62.66) | 118(75.64) | 38(24.36) | ||
| Medium (6–8) | 204(27.24) | 65(31.86) | 139(68.14) | 144(74.23) | 50(25.77) | ||
| High (>8) | 384(51.27) | 102(26.70) | 280(73.30) | 287(79.28) | 75(20.72) | ||
| Side effects | 0.003 | 0.055 | |||||
| None | 513(69.22) | 143(27.29) | 381(72.71) | 394(72.29) | 106(21.20) | ||
| Mild | 151(20.46) | 50(36.23) | 88(63.77) | 107(80.45) | 26(19.55) | ||
| Moderate | 56(7.53) | 18(33.33) | 36(66.67) | 34(64.15) | 19(35.85) | ||
| Severe | 21(2.79) | 9(50.00) | 9(50.00) | 10(66.67) | 5(33.33) | ||
Note:
a
Data presented are the average of two adherence assessments
b
p-value from Rao–Scott corrected Pearson χ2 test;
c
p-value from Pearson Chi-square test; CESD is the Center for Epidemiologic Studies Depression Scale